{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T01:53:52Z","timestamp":1781488432292,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16005-2","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:30:17Z","timestamp":1777365017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco"],"prefix":"10.1186","volume":"26","author":[{"given":"Hassan","family":"Errihani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narjiss","family":"Berrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"El Bachiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Jouhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Kabbaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Bourhafour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdellatif","family":"Benider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Khouchani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghizlane","family":"Belbaraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkader","family":"Acharki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Redouane","family":"Samlali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunvar Harsh","family":"Upveja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"16005_CR1","unstructured":"WHO. Breast cancer. 2021; March:1\u20137."},{"key":"16005_CR2","unstructured":"World Cancer Research Fund International. Breast cancer statistics. https:\/\/www.wcrf.org\/cancer-trends\/breast-cancer-statistics\/. Accessed 20 Sep 2022."},{"key":"16005_CR3","unstructured":"Breast Cancer. Statistics. https:\/\/www.cancer.net\/cancer-types\/breast-cancer\/statistics. Accessed 20 Sep 2022."},{"key":"16005_CR4","first-page":"5211","volume":"17","author":"M Khalis","year":"2016","unstructured":"Khalis M, Rhazi K, El, Charaka H, Chaj\u00e8s V, Rinaldi S, Nejjari C, et al. Female Breast Cancer Incidence and Mortality in Morocco: Comparison with Other Countries. Asian Pac J Cancer Prev. 2016;17:5211.","journal-title":"Asian Pac J Cancer Prev"},{"key":"16005_CR5","unstructured":"World Health Organization. International Agency for Research on Cancer. World Health Organization. Morocco; 2020."},{"key":"16005_CR6","first-page":"6254","volume":"7","author":"A Nassar","year":"2014","unstructured":"Nassar A, Khoor A, Radhakrishnan R, Radhakrishnan A, Cohen C. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas. Int J Clin Exp Pathol. 2014;7:6254\u201361.","journal-title":"Int J Clin Exp Pathol"},{"key":"16005_CR7","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Sci (1979). 1987;235:182\u201391.","DOI":"10.1126\/science.3798106"},{"key":"16005_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12905-017-0456-1","volume":"17","author":"J Bakkach","year":"2017","unstructured":"Bakkach J, Mansouri M, Derkaoui T, Loudiyi A, Fihri M, Hassani S, et al. Clinicopathologic and prognostic features of breast cancer in young women: a series from North of Morocco. BMC Womens Health. 2017;17:106.","journal-title":"BMC Womens Health"},{"key":"16005_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12905-016-0361-z","volume":"17","author":"M Elidrissi Errahhali","year":"2017","unstructured":"Elidrissi Errahhali M, Elidrissi Errahhali M, Ouarzane M, El Harroudi T, Afqir S, Bellaoui M. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. BMC Womens Health. 2017;17:3.","journal-title":"BMC Womens Health"},{"key":"16005_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1677\/erc.0.0090075","volume":"9","author":"M Harries","year":"2002","unstructured":"Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer. 2002;9:75\u201385.","journal-title":"Endocr Relat Cancer"},{"key":"16005_CR11","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMe058196","volume":"353","author":"GN Hortobagyi","year":"2005","unstructured":"Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005;353:1734\u20136.","journal-title":"N Engl J Med"},{"key":"16005_CR12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2003","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJPM. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. J Clin Oncol. 2003;20:719\u201326.","journal-title":"J Clin Oncol"},{"key":"16005_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.29271\/jcpsp.2019.02.159","volume":"29","author":"F Sheikh","year":"2019","unstructured":"Sheikh F, Nazir A, Yasmeen S, Badar F, Ahmad U, Siddiqui N. Pathologic complete response in HER2-positive breast cancer patients receiving trastuzumab in neoadjuvant setting. J Coll Physicians Surg Pakistan. 2019;29:159\u201363.","journal-title":"J Coll Physicians Surg Pakistan"},{"key":"16005_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med. 2001;344:783\u201392.","journal-title":"N Engl J Med"},{"key":"16005_CR15","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med. 2011;365:1273\u201383.","journal-title":"N Engl J Med"},{"key":"16005_CR16","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2\u2013Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group. J Clin Oncol. 2005;23:4265\u201374.","journal-title":"J Clin Oncol"},{"key":"16005_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/tbj.13240","volume":"25","author":"R Martinello","year":"2019","unstructured":"Martinello R, Becco P, Vici P, Airoldi M, Del Mastro L, Garrone O, et al. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. Breast J. 2019;25:444\u20139.","journal-title":"Breast J"},{"key":"16005_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10549-014-2836-7","volume":"144","author":"HT Tsai","year":"2014","unstructured":"Tsai HT, Isaacs C, Fu AZ, Warren JL, Freedman AN, Barac A, et al. Risk of cardiovascular adverse events from trastuzumab (Herceptin \u00ae) in elderly persons with breast cancer: A population-based study. Breast Cancer Res Treat. 2014;144:163\u201370.","journal-title":"Breast Cancer Res Treat"},{"key":"16005_CR19","volume-title":"Prescribing Information","year":"2010","unstructured":"Herceptin, editor. (trastuzumab) Prescribing Information. South San Francisco, CA: Genentech, Inc; 2010."},{"key":"16005_CR20","unstructured":"Herceptin. (trastuzumab). Summary of product characteristics. Hertfordshire, UK: Roche Products Limited; 2020."},{"key":"16005_CR21","doi-asserted-by":"crossref","unstructured":"Miller EM, Schwartzberg LS. Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States. Therapeutic Adv Med Oncol. 2019;11:1758835919887044.","DOI":"10.1177\/1758835919887044"},{"key":"16005_CR22","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1111\/bcp.13689","volume":"84","author":"CF Waller","year":"2018","unstructured":"Waller CF, Vutikullird A, Lawrence TE, Shaw A, Liu MS, Baczkowski M, et al. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab. Br J Clin Pharmacol. 2018;84:2336\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"16005_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2016.18305","volume":"317","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, et al. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)\u2013Positive Metastatic Breast Cancer. JAMA. 2017;317:37.","journal-title":"JAMA"},{"key":"16005_CR24","unstructured":"U.S. Food and Drug Administration. FDA approves first biosimilar for the treatment of certain breast and stomach cancers. 2017. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-biosimilar-treatment-certain-breast-and-stomach-cancers#:~:text=The U.S. Food and Drug,the HER2 gene (HER2%2B). Accessed 7 Jun 2022."},{"key":"16005_CR25","unstructured":"GaBI Online - Generics and Biosimilars Initiative. 2015."},{"issue":"15suppl","key":"16005_CR26","doi-asserted-by":"publisher","first-page":"e13024","DOI":"10.1200\/JCO.2020.38.15_suppl.e13024","volume":"38","author":"H Errihani","year":"2020","unstructured":"Errihani H, Berrada N, Khouchani M, Acharki A, Lahbabi K, Jouhadi H, et al. Safety of a trastuzumab biosimilar, used under routine clinical practice conditions in adult HER2\u2009+\u2009breast cancer patients in Morocco. J Clin Oncol. 2020;38(15suppl):e13024\u201313024.","journal-title":"J Clin Oncol"},{"key":"16005_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41416-019-0480-z","volume":"121","author":"L Barbier","year":"2019","unstructured":"Barbier L, Declerck P, Simoens S, Neven P, Vulto AG, Huys I. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. Br J Cancer. 2019;121:199\u2013210.","journal-title":"Br J Cancer"},{"key":"16005_CR28","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1111\/bph.13643","volume":"174","author":"BT Nemeth","year":"2017","unstructured":"Nemeth BT, Varga ZV, Wu WJ, Pacher P. Trastuzumab cardiotoxicity: from clinical trials to experimental studies. Br J Pharmacol. 2017;174:3727\u201348.","journal-title":"Br J Pharmacol"},{"key":"16005_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ctrv.2010.09.001","volume":"37","author":"T Chen","year":"2011","unstructured":"Chen T, Xu T, Li Y, Liang C, Chen J, Lu Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis. Cancer Treat Rev. 2011;37:312\u201320.","journal-title":"Cancer Treat Rev"},{"key":"16005_CR30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1517\/14740338.5.5.619","volume":"5","author":"KL Smith","year":"2006","unstructured":"Smith KL, Dang C, Seidman AD. Cardiac dysfunction associated withtrastuzumab. Expert Opin Drug Saf. 2006;5:619\u201329.","journal-title":"Expert Opin Drug Saf"},{"key":"16005_CR31","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M. Stewart and DK. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. J Clin Oncol. 2002;20:4119\u201320.","journal-title":"J Clin Oncol"},{"key":"16005_CR32","doi-asserted-by":"crossref","unstructured":"Aitelhaj M, LKhoyaali S, Rais G, Boutayeb S, Errihani H. First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study. Pan Afr Med J. 2016;24:324.","DOI":"10.11604\/pamj.2016.24.324.4058"},{"key":"16005_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/1756-0500-6-339","volume":"6","author":"M Aitelhaj","year":"2013","unstructured":"Aitelhaj M, Lkhouyaali S, Rais G, Mohtaram A, Raissouni S, Ghissassi B, et al. Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: Observational monocentric study of about 100 patients. BMC Res Notes. 2013;6:339.","journal-title":"BMC Res Notes"},{"key":"16005_CR34","first-page":"47","volume":"7","author":"L Akhouayri","year":"2018","unstructured":"Akhouayri L, Regragui M, Karkour M. HER2 breast cancer group in Morocco: A pathological and statistical study. Mol Biol. 2018;7:47.","journal-title":"Mol Biol"},{"key":"16005_CR35","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1200\/JCO.2017.74.0126","volume":"36","author":"X Pivot","year":"2018","unstructured":"Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn J-H, et al. Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2\u2013Positive Early. J Clin Oncol. 2018;36:968\u201374.","journal-title":"J Clin Oncol"},{"key":"16005_CR36","doi-asserted-by":"crossref","unstructured":"Chen S, Liang Y, Feng Z, Wang M. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis. BMC Cancer. 2019;19(1):973.","DOI":"10.1186\/s12885-019-6132-0"},{"key":"16005_CR37","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2015;372:724\u201334.","journal-title":"N Engl J Med"},{"key":"16005_CR38","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/1078-0432.CCR-07-4636","volume":"14","author":"CC Portera","year":"2008","unstructured":"Portera CC, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U, et al. Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Clin Cancer Res. 2008;14:2710\u20136.","journal-title":"Clin Cancer Res"},{"key":"16005_CR39","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","volume":"28","author":"J Baselga","year":"2010","unstructured":"Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2\u2013Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. J Clin Oncol. 2010;28:1138\u201344.","journal-title":"J Clin Oncol"},{"key":"16005_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10549-021-06197-5","volume":"188","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Pennella EJ, Gopalakrishnan U, Hernandez-Bronchud M, Herson J, Koch HF, et al. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2021;188:369\u201377.","journal-title":"Breast Cancer Res Treat"},{"key":"16005_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.clbc.2019.02.008","volume":"19","author":"N Woodward","year":"2019","unstructured":"Woodward N, De Boer RH, Redfern A, White M, Young J, Truman M, et al. Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE). Clin Breast Cancer. 2019;19:216\u201324.","journal-title":"Clin Breast Cancer"},{"key":"16005_CR42","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1634\/theoncologist.2015-0321","volume":"21","author":"AF Yu","year":"2016","unstructured":"Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, et al. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Oncologist. 2016;21:418\u201324.","journal-title":"Oncologist"},{"key":"16005_CR43","doi-asserted-by":"crossref","unstructured":"Takahashi M, Ohtani S, Nagai SE, Takashima S, Yamaguchi M, Tsuneizumi M, et al. The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study. Breast Cancer Res Treat. 2020.","DOI":"10.1007\/s10549-020-05921-x"},{"key":"16005_CR44","doi-asserted-by":"crossref","unstructured":"Silva AM da, Paulo JA de, Watanabe TT, Dib GVC. Biosimilar trastuzumab active post-marketing surveillance real-world data update: Results from a patient support program for patients under treatment with the first biosimilar trastuzumab approved in Brazil. J Clin Oncol. 2020;38(15suppl):e15626\u201315626.","DOI":"10.1200\/JCO.2020.38.15_suppl.e15626"},{"key":"16005_CR45","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1517\/13543776.2014.964683","volume":"24","author":"KM Nelson","year":"2014","unstructured":"Nelson KM, Gallagher PC. Biosimilars lining up to compete with Herceptin-opportunity knocks. Expert Opin Ther Pat. 2014;24:1149\u201353.","journal-title":"Expert Opin Ther Pat"},{"key":"16005_CR46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.breast.2016.11.014","volume":"31","author":"Y Chavarri-Guerra","year":"2017","unstructured":"Chavarri-Guerra Y, St. Louis J, Bukowski A, Soto-Perez-de-Celis E, Liedke PER, Symecko H, et al. Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011. Breast. 2017;31:197\u2013201.","journal-title":"Breast"},{"key":"16005_CR47","first-page":"1","volume":"8","author":"S Boutayeb","year":"2010","unstructured":"Boutayeb S, Boutayeb A, Ahbeddou N, Boutayeb W, Ismail E, Tazi M, et al. Estimation of the cost of treatment by chemotherapy for early breast cancer in Morocco. Cost Eff Resource Allocation. 2010;8:1\u20136.","journal-title":"Cost Eff Resource Allocation"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16005-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16005-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16005-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T01:46:16Z","timestamp":1781487976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16005-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16005"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16005-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients provided informed consent to participate in the study and authorized the collection and processing of their clinical data before inclusion in the HERLife program. The study was conducted in accordance with the regulations of Morocco authorities. Ethics approval was obtained from FDA-certified ethics committees comit\u00e9 d\u2019\u00e9thique pour la recherche biom\u00e9dicale and Universit\u00e9 Mohammed V de Rabat \u2013 Facult\u00e9 de m\u00e9decine et de Pharmacie de Rabat (approval number:46\/20) and the National Control Commission for the Protection of Personal Data (CNDP) (approval number: A-R-S-184\/2020), and Institutional leaders of the sites where the research was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Kunvar Harsh Upveja is working as a full-term employee of Biocon Biologics Limited and other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"750"}}